INCY vs. RVTY: Incyte vs. Revvity Stock Comparison

November 11, 2026

How do Incyte (INCY) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Incyte (INCY) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Company profile comparison for Incyte (INCY) and Revvity (RVTY)
Profile Item	INCY	RVTY
Name	Incyte Corp.	Revvity Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	24.39 billion USD	17.31 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	November 4, 1993	February 21, 1973
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

INCY

RVTY

GSPC

Incyte (INCY) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Incyte (INCY) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Incyte (INCY) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Incyte (INCY) and Revvity (RVTY)
Metric	INCY	RVTY
Total Return (1Y)	14.06%	76.75%
Total Return (3Y, Annualized)	32.03%	24.22%
Total Return (5Y, Annualized)	12.69%	-1.48%

Risk Profile

Drawdown History

INCY

RVTY

GSPC

Incyte (INCY) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Incyte (INCY) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Incyte (INCY) and Revvity (RVTY)
Metric	INCY	RVTY
Volatility (1Y, Annualized)	33.19%	40.22%
Beta (5Y)	0.78	1.07
Max Drawdown (5Y)	-40.50%	-59.01%
Avg. Volume (3M)	1.58M	1.89M

Risk-Adjusted Performance

Risk-Return Positioning

INCY and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Incyte (INCY) and Revvity (RVTY)
Metric	INCY	RVTY
Sharpe Ratio (1Y)	0.29	1.80
Sortino Ratio (1Y)	0.46	2.90

Profitability

ROE (TTM)

Incyte (INCY) at 7.84% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for INCY.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.84%

Max: 109.18%
INCY: 7.84%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max: 109.18%
Q3: 6.23%
RVTY: 3.45%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Incyte (INCY) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both Incyte (INCY) at 6.71% and Revvity (RVTY) at 8.61% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.71%

Max: 18.05%
INCY: 6.71%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max: 18.05%
RVTY: 8.61%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Incyte (INCY) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Incyte (INCY) at 33.72% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.72%

Max: 83.12%
INCY: 33.72%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max: 83.12%
RVTY: 17.06%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Incyte (INCY) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Incyte (INCY) and Revvity (RVTY)
Metric	INCY	RVTY
ROE (TTM)	7.84%	3.45%
ROA (TTM)	17.78%	2.54%
Net Margin (TTM)	6.71%	8.61%
Operating Margin (TTM)	33.72%	17.06%
Gross Margin (TTM)	56.02%	55.91%

Growth

Revenue Growth

Both Incyte (INCY) at 21.22% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Incyte (INCY) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Revvity (RVTY) at -5.91%, which is closer to a typical peer reading.

Incyte (INCY) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Incyte (INCY) and Revvity (RVTY)
Metric	INCY	RVTY
Revenue Growth (YoY)	21.22%	3.67%
Revenue Growth (3Y CAGR)	14.84%	-4.82%
EPS Growth (YoY)	4,173.33%	-5.91%
EPS Growth (3Y CAGR)	61.56%	-23.26%

Financial Strength

Current Ratio (MRQ)

Both Incyte (INCY) at 3.84 and Revvity (RVTY) at 2.65 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.84

Max: 25.13
Q3: 12.13
Median: 5.52
INCY: 3.84
Q1: 2.47
Min: 0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max: 25.13
Q3: 12.13
Median: 5.52
RVTY: 2.65
Q1: 2.47
Min: 0.10

Incyte (INCY) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while Revvity (RVTY) at 0.38 runs a more typical debt-to-equity mix.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
INCY: 0.01
Min: 0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max: 1.42
Q3: 0.65
RVTY: 0.38
Median: 0.15
Q1: 0.02
Min: 0.00

Incyte (INCY) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Incyte (INCY) and Revvity (RVTY)
Metric	INCY	RVTY
Current Ratio (MRQ)	3.84	2.65
Debt / Equity (MRQ)	0.01	0.38
Net Debt / EBITDA	-1.88	2.43

Dividends

Dividend Yield (TTM)

Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY: 0.19%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Incyte (INCY) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY: 13.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Incyte (INCY) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Incyte (INCY) and Revvity (RVTY)
Metric	INCY	RVTY
Dividend Yield (TTM)	0.00%	0.19%
Dividend Payout Ratio (TTM)	0.00%	13.40%

Valuation

P/E Ratio (TTM)

Both Incyte (INCY) at 61.05 and Revvity (RVTY) at 68.94 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

61.05

Max: 85.34
INCY: 61.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max: 85.34
RVTY: 68.94
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Incyte (INCY) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Incyte (INCY) at 4.06 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.06

Max: 58.18
Q3: 25.77
Median: 7.30
INCY: 4.06
Q1: 3.01
Min: 0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max: 58.18
Q3: 25.77
Median: 7.30
RVTY: 5.88
Q1: 3.01
Min: 0.01

Incyte (INCY) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Incyte (INCY) at 4.33 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.33

Max: 13.53
Q3: 6.54
INCY: 4.33
Median: 3.25
Q1: 1.69
Min: -5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max: 13.53
Q3: 6.54
Median: 3.25
RVTY: 2.39
Q1: 1.69
Min: -5.59

Incyte (INCY) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Incyte (INCY) and Revvity (RVTY)
Metric	INCY	RVTY
P/E Ratio (TTM)	61.05	68.94
P/S Ratio (TTM)	4.06	5.88
P/B Ratio (MRQ)	4.33	2.39
Free Cash Flow Yield (TTM)	5.28%	3.62%